Mouse Genome Informatics
ht
    Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       

Mild lipodystrophy with modest metabolic anomalies in Ppargtm3Yba/Pparg+ mice compared to Ppargtm2Yba/Pparg+ mice

adipose tissue
• subcutaneous fat pad is reduced but present
• however, treatment with doxycycline reverses defects observed
• brown adipocytes are pale, unilocular and hypertrophic
• however, no buffalo humps are observed and treatment wit doxycycline reverses defects observed
• authors state that defects in brown adipose tissue are the same as in Ppargtm2Yba heterozygotes
• brown adipocytes are pale, unilocular and hypertrophic
• however, treatment with doxycycline reverses defects observed
• brown adipocytes are hypertrophic
• gonadal fat pads are reduced compared to in wild-type mice
• however, treatment with doxycycline reverses defects observed

homeostasis/metabolism
• however, treatment with doxycycline reverses defects observed
• insulin levels are elevated compared to those in wild-type mice but not as high as in Ppargtm2Yba heterozygotes
• triglyceride levels are elevated compared to those in wild-type mice but not as high as in Ppargtm2Yba heterozygotes
• however, treatment with doxycycline reverses defects observed

liver/biliary system
• the liver is modestly increased in size compared to in wild-type mice
• however, treatment with doxycycline reverses defects observed

integument
• subcutaneous fat pad is reduced but present
• however, treatment with doxycycline reverses defects observed

Mouse Models of Human Disease
OMIM IDRef(s)
Lipodystrophy, Congenital Generalized, Type 2; CGL2 269700 J:125992
Lipodystrophy, Familial Partial, Type 3; FPLD3 604367 J:125992